• Home
  • Search Results
  • Standardized GMP-compliant scalable production of human pancreas organoids.

Standardized GMP-compliant scalable production of human pancreas organoids.

Stem cell research & therapy (2020-03-05)
Marta Dossena, Roberta Piras, Alessandro Cherubini, Mario Barilani, Erica Dugnani, Francesca Salanitro, Till Moreth, Francesco Pampaloni, Lorenzo Piemonti, Lorenza Lazzari

Organoids are three-dimensional in vitro-grown cell clusters that recapitulate key features of native organs. In regenerative medicine, organoid technology represents a promising approach for the replacement of severely damaged organs, such as the pancreas in patients with type 1 diabetes. Isolation human pancreas organoids (hPOs) in chemically defined serum-free culture media would be a major milestone for this approach. Starting from discarded pancreatic tissues, we developed a large-scale process for obtaining clinically relevant quantities of undifferentiated organoids, obviating enzymatic digestion and operator-dependent pancreatic ducts picking steps. hPO identity was characterized by molecular and flow cytometry analysis. This work demonstrates that it is possible to obtain a large-scale production of organoids. We introduced some innovations in the isolation, expansion, and freezing of hPOs from five donors. First of all, the choice of the starting material (islet-depleted pancreas) that allows obtaining a high quantity of hPOs at low passages. On the other hand, we introduced mechanical dissociation and we eliminated the picking step to exclude the operator-depending steps, without affecting the success of the culture (100% success rate). Another important improvement was to replace R-spondin-1 (Rspo1) conditioned medium with Rspo1 recombinant molecule to obtain a well-defined composition of the expansion medium. Finally, we implemented a GMP-compliant freezing protocol. hPOs showed exponential growth with diameter and area that increased three- and eight-fold in 7 days, respectively. Immunophenotypic profile and gene expression analysis revealed that hPOs were composed of ductal (82.33 ± 8.37%), acinar (2.80 ± 1.25%) cells, and pancreatic progenitors (5.81 ± 2.65%). This work represents a milestone for a GMP-compliance hPO production and, ultimately, their clinical application as a type 1 diabetes therapy.

Product Number
Product Description

N-Acetyl-L-cysteine, BioReagent, suitable for cell culture
Nicotinamide, BioReagent, suitable for cell culture, suitable for insect cell culture
Triton X-100, for molecular biology
TWEEN® 20, BioXtra, viscous liquid
[Leu15]-Gastrin I human, ≥95% (HPLC)
Bovine Serum Albumin solution, 30%±2% in 0.85% sodium chloride, aseptically filled